Document is current

Article History

Received: 26 June 2020

Accepted: 22 July 2020

First Online: 31 July 2020

Ethics approval and consent to participate

: This trial was reviewed and approved by the French committee for the protection of persons of CPP Ouest I on 20 January 2020 (protocol version 1.0): registration number (: NCT04307277, Eudract number: 2019–003014-13). This covers all participating centers:CHRU Besançon; Besançon, FranceInstitut Bergonié; Bordeaux, FranceCentre François Baclesse; Caen, FranceCentre Jean Perrin; Clermont-Ferrand, FranceCentre Georges-François Leclerc; Dijon, FranceCentre Antoine Lacassagne, Nice, FranceCentre Eugène Marquis, Rennes, FranceCentre Henri Becquerel, Rouen, FranceCHU Grenoble; Grenoble, FranceCHU Limoges; Limoges, FranceCentre Léon Bérard; Lyon, FranceCHU Marseille; Marseille, FranceHôpital Cochin, Paris, FranceInstitut de Cancérologie de Montpellier; Montpellier, FranceInstitut Universitaire du Cancer Toulouse Oncopole; Toulouse, FranceInstitut de Cancérologie de Lorraine - Centre Alexis Vautrin, Vandoeuvre-Les-Nancy, FranceInstitut de Cancérologie de l’Ouest - Site René Gauducheau, Saint Herblain, FranceInstitut Curie, Paris, FranceInstitut Godinot, Reims, FranceInstitut de Cancérologie de la Loire, Saint-Priez-en-Jarez, FranceInstitut de Cancérologie de Strasbourg Europe, Strasbourg, FranceInstitut Gustave Roussy, Villejuif, FranceCHU Poitiers, Poitiers, FranceInstitut Paoli-Calmettes, Marseille, FranceWritten informed consent will be obtained from all participants in the CHIC study.

: Not applicable.

: The authors have no conflict of interest to declare. The CHIC trial did not received funding from a commercial organization.